Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Bioorg Med Chem Lett. 2019 Jul 10;29(18):2695–2699. doi: 10.1016/j.bmcl.2019.07.012

Table 3.

Matched pair comparison of structures similar to erlotinib and lapatinib (13-28).

graphic file with name nihms-1537187-t0006.jpg
Compound R1 R2 X R3 Mtb signala,b WS-1c
5 μM 10 μM 20 μM (μM)
13 CF3 H CH 3,4,5-(OMe)3 1.23 1.14 1.21 >100
14 CF3 H N 3,4,5-(OMe)3 1.25 1.12 1.06 >100
15 Br H CH 3,4,5-(OMe)3 1.35 1.41 1.28 >100
16 OMe OMe CH 3,4,5-(OMe)3 1.26 1.11 1.06 >100
17 OMe OMe N 3,4,5-(OMe)3 1.03 1.01 0.94 >100
18 OMe OMe CN 3,4,5-(OMe)3 1.03 1.01 0.97 >100
19 6,7-(OCH2CH2OMe)2 N 3,4,5-(OMe)3 1.02 0.96 0.87 >100
20 6,7-(OCH2CH2OMe)2 CH 3-Ethynyl 0.88 0.79 0.58 >100
21 OMe OMe CH 3-Ethynyl 1.02 0.89 0.67 >100
22 OMe OMe N 3-Ethynyl 0.93 0.83 0.69 >100
23 OMe OMe CN 3-Ethynyl 1.08 1.03 0.98 >100
24 OMe OMe CH 3-Bromo 1.03 0.90 0.6 9.6
25 OMe OMe N 3-Bromo 0.98 0.71 0.65 3.9
26 OMe OMe CN 3-Bromo 0.88 0.56 0.37 11
27 OMe OMe N 3-Cl-4-(2-F-PhO) 0.92 0.74 0.80 1.1
28 OMe OMe CH 3-Cl-4-(2-F-PhO) 0.78 0.22 0.10 11
a

Relative luminescence was measured at 3 days after treatment. Values = RLU(sample)/RLU(no compound);

b

None of the compounds reduced the relative Mtb signal below 95 % at 1.3 or 2.5 μM;

c

IC50 (mean average n = 4), 48 h